Adhesive Capsulitis (Frozen Shoulder)

**Adhesive capsulitis (frozen shoulder)** is a condition where the shoulder joint capsule — the flexible tissue envelope surrounding the ball-and-socket joint — becomes inflamed, thickened, and contracted, resulting in severe stiffness and pain. The capsule develops dense adhesions (scar-like tissue) that physically restrict movement. The condition typically progresses through **three distinct stages**: **Stage 1: Freezing (2-9 months)** — Gradual onset of diffuse shoulder pain that worsens progressively. Range of motion begins to decrease. Pain is the dominant symptom, often severe at night. This is when most patients seek medical attention. **Stage 2: Frozen (4-12 months)** — Pain may actually improve, but stiffness is at its worst. The shoulder is "locked" with severely limited range of motion in all directions. External rotation and abduction are most restricted. Daily activities become very difficult. **Stage 3: Thawing (5-24 months)** — Range of motion gradually improves spontaneously. Pain continues to decrease. Recovery is slow but progressive. Some patients regain full motion; others retain a mild permanent restriction. The total duration from onset to resolution averages **1-3 years**, though some cases resolve faster with treatment and others persist longer. The capsular contracture is similar to the fibrotic process seen in [Dupuytren's contracture](/condition/dupuytrens-contracture) — involving excessive collagen deposition and myofibroblast activity.

The exact cause of **primary (idiopathic) adhesive capsulitis** remains incompletely understood, but research has identified key mechanisms: **The Capsular Inflammation-Fibrosis Cycle:** 1. **Initial inflammation** — The synovial lining of the joint capsule becomes inflamed (synovitis), releasing inflammatory cytokines (IL-1, IL-6, TNF-alpha, TGF-beta) 2. **Fibroblast activation** — Inflammation stimulates capsular fibroblasts to transform into **myofibroblasts** — contractile cells that produce excessive collagen 3. **Capsular thickening** — Dense collagen deposition and adhesion formation thicken the capsule, particularly in the **rotator interval** and **axillary recess** (the folds that allow full range of motion) 4. **Capsular contracture** — Myofibroblasts actively contract, shrinking the capsule volume from a normal ~20-30 mL to as little as 5-10 mL 5. **Motion restriction** — The contracted, thickened capsule physically prevents the humeral head from moving through its normal range **Why Diabetes Is the #1 Risk Factor:** Elevated blood glucose causes **advanced glycation end-products (AGEs)** to accumulate in collagen. AGEs create abnormal collagen cross-links, making the capsule stiffer and more prone to fibrosis. Diabetic patients also have impaired microvascular circulation to the capsule, reducing tissue health. The risk correlates with **HbA1c level** — poorly controlled diabetes carries higher risk. **The Dupuytren's Connection:** Frozen shoulder and [Dupuytren's contracture](/condition/dupuytrens-contracture) share the same pathological process — excessive myofibroblast-driven fibrosis. Both involve abnormal TGF-beta signaling. Having Dupuytren's increases frozen shoulder risk 4-7x, and both conditions are more common in diabetes. Some researchers consider them part of a "fibromatosis spectrum." **Autoimmune Hypothesis:** The association with thyroid disease, diabetes (type 1), and other autoimmune conditions — plus the finding of elevated HLA-B27 in some patients — suggests an autoimmune component in predisposed individuals.

Treatment of frozen shoulder is **stage-dependent** — the approach differs based on whether the patient is in the freezing, frozen, or thawing stage: **Stage 1 (Freezing) — Focus: Pain Control + Gentle Motion** - **Corticosteroid injection** (intra-articular) — The most effective early intervention. A single injection reduces pain significantly and may shorten the freezing phase. Meta-analyses show corticosteroid injections provide **superior pain relief and faster recovery** compared to physical therapy alone in the first 6 weeks. Ultrasound-guided injection improves accuracy to 90%+ vs 60-70% for landmark-guided. - **Oral NSAIDs or acetaminophen** for pain management - **Gentle range-of-motion exercises** within pain tolerance (pendulum exercises, passive stretching) — aggressive stretching in this stage WORSENS inflammation - **Physical therapy** focused on pain modulation (heat, manual therapy) and gentle mobilization **Stage 2 (Frozen) — Focus: Stretching + Mobilization** - **Intensive physical therapy** — the cornerstone of frozen stage treatment. Stretching into all restricted directions (external rotation, abduction, flexion) with sustained holds. Joint mobilizations (Maitland grades III-IV). - **Home exercise program** — critical for success. 4-6 daily stretching sessions producing significant gains over 6-12 weeks - **Hydrodilatation (distension arthrography)** — injection of saline + steroid to expand/rupture the contracted capsule. Moderate evidence of benefit; often combined with manipulation. Can increase joint volume from 5 mL to 20+ mL. - **Repeat corticosteroid injection** if pain is preventing rehabilitation progress **Stage 3 (Thawing) — Focus: Strengthening + Function** - Continue stretching to regain remaining range of motion - Begin **strengthening exercises** for the rotator cuff and periscapular muscles - Functional rehabilitation — practicing movements needed for daily activities **Interventional Options (if conservative treatment fails after 6+ months):** - **Manipulation under anesthesia (MUA)** — The surgeon forcefully moves the shoulder through its full range while the patient is under general anesthesia, breaking the capsular adhesions. Effective in 70-90% of cases. Risk: humeral fracture (rare), [rotator cuff tear](/condition/rotator-cuff-tear), brachial plexus injury. - **Arthroscopic capsular release** — Surgical cutting of the contracted capsule using an arthroscope. 85-95% success rate. Can be combined with MUA. Preferred in diabetics (who have higher recurrence with MUA alone). - **MUA + hydrodilatation** — Combined approach with good evidence **Prognosis:** - **90% of patients** improve with conservative treatment (physical therapy ± corticosteroid injections) - Average time to resolution: 1-3 years - **20-50% of patients** retain some degree of permanent motion loss (usually mild and not functionally limiting) - **Diabetic patients** tend to have more severe disease and slower, less complete recovery